Viewing StudyNCT05455619

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 5:50 PM
Last Modification Date: 2024-10-26 @ 2:37 PM
Study NCT ID: NCT05455619
Status: RECRUITING
Last Update Posted: 2024-05-22
First Post: 2022-06-22
Brief Title: Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Women With a PI3K Alteration and HRHer2- Breast Cancer
Sponsor: SynDevRx Inc
Organization: SynDevRx Inc
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Metastatic Breast Cancer
HRHER2-negative Breast Cancer
Keywords:
Name View
hyperglycemia View
insulin View
glucose View
SDX-7320 View
fulvestrant View
apelisib View
PIK3CA mutation View
evexomostat View
HR Her2- metastatic breast cancer View
hyperinsulinemia View
capivasertib View
AKT View
PTEN View